Literature DB >> 31004678

Heparanase protects the heart against chemical or ischemia/reperfusion injury.

Fulong Wang1, Thomas Pulinilkunnil2, Stephane Flibotte3, Corey Nislow1, Israel Vlodavsky4, Bahira Hussein1, Brian Rodrigues5.   

Abstract

Although cancer cells use heparanase for tumor metastasis, favourable effects of heparanase have been reported in the management of Alzheimer's disease and diabetes. Indeed, we previously established a protective function for heparanase in the acutely diabetic heart, where it conferred cardiomyocyte resistance to oxidative stress and apoptosis by provoking changes in gene expression. In this study, we tested if overexpression of heparanase can protect the heart against chemically induced or ischemia/reperfusion (I/R) injury. Transcriptomic analysis of Hep-tg hearts reveal that 240 genes related to the stress response, immune response, cell death, and development were altered in a pro-survival direction encompassing genes promoting the unfolded protein response (UPR) and autophagy, as well as those protecting against oxidative stress. The observed UPR activation was adaptive and not apoptotic, was mediated by activation of ATF6α, and when combined with mTOR inhibition, induced autophagy. Subjecting wild type (WT) mice to increasing concentrations of the ER stress inducer thapsigargin evoked a transition from adaptive to apoptotic UPR, an effect that was attenuated in Hep-tg mouse hearts. Consistent with these observations, when exposed to I/R, the infarct size and markers of apoptosis were significantly lower in the Hep-tg heart compared to WT. Finally, UPR and autophagy inhibitors reduced the protective effects of heparanase overexpression during I/R. Our data suggest that the mechanisms that underlie the role of heparanase in promoting cell survival could be uniquely beneficial to the heart by providing protection against cellular stresses, and could be useful for exploitation as a therapeutic target for the treatment of heart disease.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Autophagy; Cardioprotection; Energy balance; Heparanase; Unfolded protein response

Mesh:

Substances:

Year:  2019        PMID: 31004678     DOI: 10.1016/j.yjmcc.2019.04.008

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  4 in total

1.  Inhibition of heparanase protects against pancreatic beta cell death in streptozotocin-induced diabetic mice via reducing intra-islet inflammatory cell infiltration.

Authors:  Wen-Yu Song; Xiao-Han Jiang; Ying Ding; Yan Wang; Ming-Xuan Zhou; Yun Xia; Chen-Yu Zhang; Chong-Chong Yin; Chen Qiu; Kai Li; Peng Sun; Xiao Han
Journal:  Br J Pharmacol       Date:  2020-08-19       Impact factor: 8.739

2.  [Down-regulation of SIK2 expression alleviates myocardial ischemia-reperfusion injury in rats by inhibiting autophagy through the mTOR-ULK1 signaling pathway].

Authors:  X Liu; L Xu; J Wu; Y Zhang; C Wu; X Zhang
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2022-07-20

3.  [Heparanase promotes trans-endothelial migration of hepatocarcinoma cells by inducing apoptosis of microvascular endothelial cells].

Authors:  Xiaopeng Chen; Rui Ye; Dafei Dai; Yuhai Wu; Yuanlin Yu; Bin Cheng
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2020-08-30

4.  Beta-cell specific Insr deletion promotes insulin hypersecretion and improves glucose tolerance prior to global insulin resistance.

Authors:  Søs Skovsø; Evgeniy Panzhinskiy; Jelena Kolic; Haoning Howard Cen; Derek A Dionne; Xiao-Qing Dai; Rohit B Sharma; Lynda Elghazi; Cara E Ellis; Katharine Faulkner; Stephanie A M Marcil; Peter Overby; Nilou Noursadeghi; Daria Hutchinson; Xiaoke Hu; Hong Li; Honey Modi; Jennifer S Wildi; J Diego Botezelli; Hye Lim Noh; Sujin Suk; Brian Gablaski; Austin Bautista; Ryekjang Kim; Corentin Cras-Méneur; Stephane Flibotte; Sunita Sinha; Dan S Luciani; Corey Nislow; Elizabeth J Rideout; Eric N Cytrynbaum; Jason K Kim; Ernesto Bernal-Mizrachi; Laura C Alonso; Patrick E MacDonald; James D Johnson
Journal:  Nat Commun       Date:  2022-02-08       Impact factor: 14.919

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.